A61K 39/001
Preparations to induce tolerance to non-self
Official title: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
A61K39/001 (Preparations to induce tolerance to non-self) appears on 407 US grants and 736 published applications in this corpus.
Search patents in A61K- Granted patents
- 407
- Published applications
- 736
- Assignees
- 310
- Inventors
- 911
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 13 | 0 |
| 1998 | 4 | 0 |
| 1999 | 11 | 0 |
| 2000 | 6 | 0 |
| 2001 | 15 | 4 |
| 2002 | 13 | 35 |
| 2003 | 14 | 27 |
| 2004 | 6 | 33 |
| 2005 | 5 | 24 |
| 2006 | 10 | 22 |
| 2007 | 5 | 9 |
| 2008 | 8 | 13 |
| 2009 | 6 | 20 |
| 2010 | 9 | 21 |
| 2011 | 10 | 21 |
| 2012 | 10 | 35 |
| 2013 | 8 | 21 |
| 2014 | 14 | 15 |
| 2015 | 10 | 43 |
| 2016 | 24 | 47 |
| 2017 | 20 | 31 |
| 2018 | 32 | 52 |
| 2019 | 20 | 46 |
| 2020 | 18 | 39 |
| 2021 | 30 | 37 |
| 2022 | 15 | 30 |
| 2023 | 18 | 33 |
| 2024 | 16 | 32 |
| 2025 | 20 | 28 |
| 2026 | 10 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inducing immune tolerance8 Sep 2026US 12,728,155 B2Anokion SA
- Universal donor stem cells and related methods23 Jun 2026US 12,662,657 B2President and Fellows of Harvard College
- Peptide antigens and uses thereof16 Jun 2026US 12,653,873 B2Humanitas Mirasole S.P.A.
- HLA class II deficient cells, HLA class I deficient cells capable of expressing HLA class II proteins, and uses thereof26 May 2026US 12,636,354 B2University of Washington through its Center for Commercialization
- Immunomodulatory cells and uses thereof12 May 2026US 12,622,932 B2Sinai Health System
- Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof3 Sep 2026US 2026/0256896 A1University of Washington through its Center for Commercialization
- Stem cells for transplantation and manufactauring method therefor20 Aug 2026US 2026/0240952 A1National Center of Neurology and Psychiatry
- Treatment of atopic dermatitis using self-replicating rna expressing il-3120 Aug 2026US 2026/0240967 A1Ceva Sante Animale
- Methods for inducing immune tolerance6 Aug 2026US 2026/0224677 A1Translate Bio, Inc.
- Immunomodulatory cells and uses thereof30 Jul 2026US 2026/0216252 A1Sinai Health System
Most cited
By later US patents
- Mesenchymal stem cells for prevention and treatment of immune responses in transplantation181US 6,328,960 B1Osiris Therapeutics, Inc. · 2001
- Method of preparing suppressor T cells with allogeneic mesenchymal stem cells149US 6,281,012 B1Osiris Therapeutics, Inc. · 2001
- Tolerogenic synthetic nanocarriers for inducing regulatory B cells129US 8,652,487 B2Selecta Biosciences, Inc. · 2014
- Mesenchymal stem cells for prevention and treatment of immune responses in transplantation118US 6,875,430 B2Osiris Therapeutics, Inc. · 2005
- Mesenchymal stem cells for prevention and treatment of immune responses in transplantation103US 6,368,636 B1Osiris Therapeutics, Inc. · 2002